Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

被引:97
作者
Lam, J
Nelson, CA
Ross, FP
Teitelbaum, SL
Fremont, DH
机构
[1] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA
[2] Washington Univ, Dept Biochem & Mol Biophys, Sch Med, St Louis, MO 63110 USA
基金
英国惠康基金;
关键词
D O I
10.1172/JCI13890
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
RANK, the receptor activator of NF-kappaB, and its ligand RANKL (initially termed TRANCE, also termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs associate with high specificity. Given the low level of amino acid conservation among members of the TNF superfamily, the means by which these molecules achieve specificity cannot be completely understood without knowledge of their three-dimensional structures. To determine the elements of RANKL that mediate RANK activation, we have crystallized the ectodomain of murine RANKL and solved its structure to a resolution of 2.6 Angstrom. RANKL self-associates as a homotrimer with four unique surface loops that distinguish it from other TNF family cytokines. Mutagenesis of selected residues in these loops significantly modulates RANK activation, as evidenced by in vitro osteoclastogenesis, thereby establishing their necessity in mediating the biological activities of RANKL Such structural determinants of RANKL-RANK specificity may be of relevance in the pharmacologic design of compounds to ameliorate osteopenic disorders of bone.
引用
收藏
页码:971 / 979
页数:9
相关论文
共 39 条
[31]
Processing of X-ray diffraction data collected in oscillation mode [J].
Otwinowski, Z ;
Minor, W .
MACROMOLECULAR CRYSTALLOGRAPHY, PT A, 1997, 276 :307-326
[32]
The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor [J].
Shapiro, L ;
Scherer, PE .
CURRENT BIOLOGY, 1998, 8 (06) :335-338
[33]
Bone resorption by osteoclasts [J].
Teitelbaum, SL .
SCIENCE, 2000, 289 (5484) :1504-1508
[34]
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection [J].
Teng, YTA ;
Nguyen, H ;
Gao, XJ ;
Kong, YY ;
Gorczynski, RM ;
Singh, B ;
Ellen, RP ;
Penninger, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) :R59-R67
[35]
TEUNEH A, 2000, J BIOL CHEM, V275, P23319
[36]
Expression, purification, and characterization of the human receptor activator of NF-κB ligand (RANKL) extracellular domain [J].
Willard, D ;
Chen, WJ ;
Barrett, G ;
Blackburn, K ;
Bynum, J ;
Consler, T ;
Hoffman, C ;
Horne, E ;
Iannone, MA ;
Kadwell, S ;
Parham, J ;
Ellis, B .
PROTEIN EXPRESSION AND PURIFICATION, 2000, 20 (01) :48-57
[37]
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells [J].
Wong, BR ;
Rho, JR ;
Arron, J ;
Robinson, E ;
Orlinick, J ;
Chao, M ;
Kalachikov, S ;
Cayani, E ;
Bartlett, FS ;
Frankel, WN ;
Lee, SY ;
Choi, YW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25190-25194
[38]
Characterization of structural domains of human osteoclastogenesis inhibitory factor [J].
Yamaguchi, K ;
Kinosaki, M ;
Goto, M ;
Kobayashi, F ;
Tsuda, E ;
Morinaga, T ;
Higashio, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) :5117-5123
[39]
Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL [J].
Yasuda, H ;
Shima, N ;
Nakagawa, N ;
Yamaguchi, K ;
Kinosaki, M ;
Mochizuki, S ;
Tomoyasu, A ;
Yano, K ;
Goto, M ;
Murakami, A ;
Tsuda, E ;
Morinaga, T ;
Higashio, K ;
Udagawa, N ;
Takahashi, N ;
Suda, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3597-3602